SCHEMBL23684983

SCHEMBL23684983

CC(C)N1CCN(c2nc(NC3COC3)cc(C(=O)O)n2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FPR2 P25090 2/20 0.37
▸ SCN9A Q15858 2/20 0.37
▸ ACHE P22303 2/20 0.37
▸ WHR1 P49842 3/20 0.37
▸ CCR4 P51679 1/20 0.37
▸ PRMT5 O14744 4/20 0.36
▸ WDR77 Q9BQA1 4/20 0.36
▸ PTPN11 Q06124 1/20 0.36
▸ EHMT2 Q96KQ7 1/20 0.36
▸ EHMT1 Q9H9B1 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ RBP4 P02753 1/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.35
▸ KIF18A Q8NI77 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23685049 0.89 HRH3 (0.41) FPR2SCN9AWHR1CCR4PRMT5
SCHEMBL23684020 0.88 MET (0.40) FPR2SCN9APRMT5WDR77KDM4E
SCHEMBL23684719 0.87 KDM4E (0.42) PRMT5WDR77KDM4EMEN1ALDH1A1
SCHEMBL23684624 0.86 PIK3CA (0.43) ACHEPTPN11KDM4EMEN1ALDH1A1
SCHEMBL23304360 0.85 GAA (0.40) KDM4EMEN1ALDH1A1GAATHRB
SCHEMBL23304407 0.85 ALDH1A1 (0.46) KDM4EMEN1ALDH1A1GAATHRB
SCHEMBL23684344 0.84 RAD52 (0.42) PRMT5WDR77PTPN11EHMT2EHMT1
SCHEMBL23684778 0.84 RBP4 (0.38) FPR2SCN9APRMT5WDR77KDM4E
SCHEMBL23684010 0.83 GBA1 (0.39) KDM4EMEN1ALDH1A1GAATHRB
SCHEMBL17303784 0.82 ALDH1A1 (0.48) ACHECCR4EHMT2EHMT1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11986471-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2024-05-21 — — US disclosed
US-20230060499-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20230060499-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-11077101-B1 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2021-08-03 — — US disclosed
US-11077101-B1 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2021-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11986471-B2 Compounds and methods of use XDH, F12, LPXN FPR2 298/4885SCN9A 1065/4885ACHE 375/4885
US-11077101-B1 Compounds and methods of use XDH, F12, LPXN FPR2 298/4885SCN9A 1065/4885ACHE 375/4885
US-20230060499-A1 COMPOUNDS AND METHODS OF USE XDH, F12, LPXN FPR2 298/4885SCN9A 1065/4885ACHE 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback